This week in peptide research.
Curated from our research library: what happened, what it means in plain English, how strong the evidence is, and a link to the original source.
Education only, not medical advice. Talk to a licensed clinician. Nothing here is dosing guidance.
Free this week.
Each card links to its primary source. Full briefs go deeper and are available on request.
- Regulatory
HHS files interim policy on compounding six peptides
On Oct 28, HHS filed an interim enforcement-discretion policy (RIN 0910-ZD94) for licensed 503A compounding pharmacies covering BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. It sets conditions, including a patient-specific prescription and a registered ingredient source. It is not FDA approval, it does not cover "research use only" sales, and WADA still bans BPC-157 and TB-500 in sport. It publishes in the Federal Register on Oct 30, followed by a 2-week public comment period.
- Phase 3 started
Oral VK2735 enters Phase 3 (SUNRISE-1 and SUNRISE-2)
Viking started two 68-week Phase 3 trials of its once-daily GLP-1/GIP tablet, one in people with obesity or overweight and one in people who also have type 2 diabetes. Results are years away.
- Human RCT
UBT251 Phase 2 obesity results published in Cell Metabolism
In a 24-week randomized trial of 205 adults without type 2 diabetes, average weight change was about −13.6% to −19.7% across UBT251 groups versus −2.0% with placebo. It is an investigational drug, not available outside trials.
Source: PubMed 42843337
- News report
Death reports tied to black-market “retatrutide”
CBS News reported FDA adverse-event filings, including deaths, involving products sold as retatrutide from unregulated sources. Such reports do not prove the product caused the deaths, and retatrutide is not approved for any use.
Source: CBS News
- Human RCT
Rusfertide VERIFY Phase 3 published in J Clin Oncol
In 293 people with polycythemia vera who depended on phlebotomy, 77% on rusfertide met the trial’s response goal versus 33% on placebo, and they needed fewer phlebotomies.
Source: PubMed 42868322
- Human RCT
Survodutide SYNCHRONIZE-2 published in NEJM
In 752 adults with type 2 diabetes and overweight or obesity, average weight change at 76 weeks was −8.2% and −9.8% on two survodutide doses versus −3.9% on placebo. Survodutide remains investigational.
Source: PubMed 42820639
- Trial registered
MariTide home autoinjector Phase 3 registered
Amgen registered a Phase 3 study (about 230 people) of self-administration at home with an autoinjector for maridebart cafraglutide. It is not yet recruiting.
Source: ClinicalTrials.gov NCT07871409
Behind the briefs.
Library: ~117 peptide profiles across 12 topics, 970+ papers tracked.
Full briefs cover study design, who was studied, limits, and open questions. They are shared individually, not posted publicly. No downloads.
Want help putting research in context?
Book coaching with Coach Elias J: $160 in person (60 minutes, San Francisco) or $110 virtual. Medical questions stay with your licensed clinician.